0001688757-26-000022
SEC filingRevenue grew 27.2% to $211.1M driven by US FDA approval, with gross margin expanding to 69.3%, and net loss improved to $51.1M.
Establishment Labs Holdings Inc. is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market. The company was incorporated in Costa Rica in 2004 and reorganized under a British Virgin Islands holding company in 2013. Its primary revenue driver is the Motiva Implants line of silicone gel-filled breast implants, which have been sold in over 100 countries since commercial launch in October 2010.
The business section does not explicitly define separate reporting segments. The company appears to operate as a single segment centered on breast implants and related technologies.
The company's portfolio includes five product families of Motiva Implants: Round and Ergonomix Round, Ergonomix Oval, Anatomical TrueFixation, Ergonomix2 Round and Ergonomix2 Diamond, and the Flora Tissue Expander. Key proprietary technologies include SmoothSilk/SilkSurface shell surface, Qid and ZEN RFID microtransponders for traceability, BluSeal visual barrier layer, and TrueMonobloc gel-shell-patch construction. The company also offers minimally invasive systems: Preservé (launched February 2025) and Mia Femtech (launched April 2023). The Motiva Flora Tissue Expander is the first MRI conditional expander with integrated RFID port.
Products are sold through exclusive distributors in most countries, with direct sales forces in the United States, Brazil, Argentina, and several European countries. As of December 31, 2025, the sales organization included 278 employees and contractors. The company offers a comprehensive warranty program, including the Motiva Always Confident Warranty, covering rupture and capsular contracture. No significant customer concentration is disclosed.
The U.S. market is concentrated among Allergan Aesthetics (AbbVie), Mentor Worldwide (Johnson & Johnson), and Sientra (Tiger Aesthetics Medical). Internationally, competitors include GC Aesthetics, Silimed, Groupe Sebbin, Hans Biomed, Polytech Health & Aesthetics, and Arion Laboratories. The company believes its competitive advantages include safety data, proprietary technologies, and vertically integrated manufacturing.
Key strategic pillars include: expanding U.S. market revenues following FDA PMA approval in September 2024; growing revenues in existing markets through Motiva Implants and new products like Preservé and Mia Femtech; optimizing patient conversion via marketing programs including social media, influencers, and physician education; pursuing strategic acquisitions to complement the portfolio; and maintaining high engagement with key opinion leaders through medical educational events (607 events in 2025).
As of December 31, 2025, the company employed 1,004 people. None are unionized except for certain employees in Brazil and Argentina. The company emphasizes attracting and retaining qualified personnel through equity and cash incentive plans and a safe, inclusive workplace.
Revenue for fiscal year 2025 reached $211.1 million, a 27.2% increase from $166.0 million in 2024. The growth was primarily fueled by the U.S. commercial launch following FDA approval in September 2024, which contributed $45.6 million in sales. Gross profit rose 33.6% to $146.3 million, and gross margin expanded to 69.3% from 66.0%, driven by higher average selling prices in the U.S. market. Operating loss improved 22.0% to $39.0 million, as revenue growth outpaced operating expense increases. Net loss narrowed to $51.1 million from $84.6 million, aided by a $7.0 million income tax benefit from the release of a valuation allowance on deferred tax assets.
Management expects overall operating expenses to increase in 2026 as commercial and operational activities expand following the U.S. launch. The company remains focused on managing expenses but anticipates higher SG&A and R&D costs related to clinical trials (IDE and post-approval study) and product development. Key strategic priorities include expanding U.S. market presence, launching Preservé in additional countries including full U.S. launch in 2026, and continuing to invest in clinical data. No specific revenue or margin guidance was provided.
As of December 31, 2025, the company held $75.6M in cash and cash equivalents, down from $90.3M at year-end 2024. Total assets were $357.2M, with inventory the largest current asset at $85.6M (net of $3.9M reserve). The allowance for credit losses increased to $6.8M from $3.1M. Shareholders' equity decreased to $23.5M from $53.1M, driven by the net loss. The company's primary debt is the Oaktree credit facility with a carrying value of $247.5M (principal $246.4M) maturing April 2027. Additionally, short-term borrowings of $12.4M were outstanding for silicone purchases and insurance premiums. The effective interest rate on the Oaktree debt is 10.9%, with an interest coverage ratio not applicable due to operating loss. The company was in compliance with all financial covenants.
The Notes disclose no material purchase commitments beyond the Avantor master supply agreement (expiring Dec 2026, currently under renegotiation). The contingency section reports no material contingent liabilities. The company has an Inventory Funding Agreement with RTW for up to $10M, of which $10M was drawn at year-end. Operating lease liabilities total $4.5M, with future payments of $5.4M through 2030. No other significant contractual obligations were identified.
Buybacks and Dividends: The company has no share repurchase programs or dividend payments. Debt: In September 2025, the company drew $24.5M (net) under the Oaktree Tranche D Term Loan, increasing total principal to $246.4M. No principal repayments were made. The weighted-average interest rate is 9.2%, and the effective rate is 10.9%. Interest expense was $25.3M in 2025. Capex: Capital expenditures for property and equipment were $6.0M, or 2.9% of revenue, down from $8.5M in 2024. The New manufacturing facility in Costa Rica was completed in June 2024, so capex normalized.
The company operates as a single reportable segment. Revenue by geography for 2025: EMEA $91.1M (43%), North America $45.6M (22%), Asia-Pacific $34.5M (16%), Latin America $39.9M (19%). North America revenue surged due to U.S. FDA approval in September 2024. Operating loss improved to $39.0M from $50.0M, driven by gross margin expansion (69.3% vs 66.0%) and SG&A leverage.
Establishment Labs faces significant regulatory uncertainty. The FDA approval for Motiva Implants (Sept 2024) is recent, and the company must comply with post-approval studies (10-year patient monitoring) and the transition from QSR to QMSR by Feb 2026. Any non-compliance could trigger enforcement actions. The EU MDR recertification process is lengthy (13–18 months), and the political environment (US tariffs under Trump administration, potential government shutdowns) adds unpredictability. The company also notes exposure to emerging markets (Brazil, Latin America) with political instability and currency crises.
A critical risk is sole reliance on Avantor for medical-grade silicone—a single point of failure. The company also depends on single-source suppliers for packaging and sterilization (EtO). Disruptions at any point (natural disaster, labor dispute, regulatory shutdown) could halt manufacturing. The Costa Rica facility is subject to earthquake/volcanic risk. Despite recent capacity expansion, demand forecasting errors could lead to stockouts or excess inventory write-offs.
Motiva Implants face entrenched competitors (Mentor, Allergan) with extensive US clinical data and brand recognition. Pricing pressure is intense, especially in price-sensitive markets. The company's limited US operating history means it lacks long-term market data to guide strategy. Additionally, negative publicity around BIA-ALCL and BII—even if not linked to Motiva—could reduce global demand. Counterfeit products in emerging markets pose reputational and liability risks.
Revenue is heavily concentrated in Motiva Implants (99% in 2025). A decline in adoption or regulatory setback would be devastating. Currency volatility is unhedged; EUR, BRL, and GBP exposure could significantly impact reported results. The company has $495.8M accumulated deficit and expects continued losses; additional capital raises would dilute shareholders. Product liability insurance is only $25M, potentially inadequate given historical industry litigation.
The company's Qid Safety Technology microtransponder creates MRI artifacts—a physician education risk. Cybersecurity threats are increasing; dependence on third-party vendors (SOC 1 compliant but not guaranteed) and exposure to EU/UK GDPR, CCPA could result in fines up to 4% of global revenue. The use of AI tools by employees may leak proprietary information or violate emerging regulations (EU AI Act).